PLAT Recombinant Monoclonal Antibody

說明書

中文名稱：

PLAT重組抗體
貨號：

CSB-RA778654A0HU
規格：

￥1320
圖片：
Overlay Peak curve showing Hela cells stained with CSB-RA778654A0HU (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1μg/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was rabbit IgG (1μg/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA778654A0HU重組單克隆抗體是針對人源PLAT（組織型纖溶酶原激活劑，tPA）研發的高特異性檢測工具。PLAT作為絲氨酸蛋白酶家族成員，在調控纖溶系統、介導纖維蛋白降解及細胞外基質重塑中發揮關鍵作用，其表達水平與多種病理生理過程密切相關。該抗體經ELISA和流式細胞術嚴格驗證，在流式應用中推薦稀釋比例為1:50-1:200，可清晰檢測細胞內源性PLAT蛋白的表達水平。其重組單克隆特性確保了批次間的高度一致性，適用于定量分析PLAT在不同細胞模型中的表達動態，如血管內皮細胞激活狀態評估、纖溶系統調控機制研究以及藥物干預下相關信號通路變化的檢測。科研人員可將其應用于體外血栓形成模型、細胞遷移實驗或基因表達調控研究，為心血管疾病、腫瘤微環境等領域的機制探索提供可靠檢測方案。
Uniprot No.：

P00750
基因名：

PLAT
別名：

Tissue-type plasminogen activator (t-PA) (t-plasminogen activator) (tPA) (EC 3.4.21.68) (Alteplase) (Reteplase) [Cleaved into: Tissue-type plasminogen activator chain A, Tissue-type plasminogen activator chain B], PLAT
反應種屬：

Human
免疫原：

A synthesized peptide derived from Human PLAT
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

32B1
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, FC

推薦稀釋比：

Application	Recommended Dilution
FC	1:50-1:200

Protocols：

ELISA Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy.
基因功能參考文獻：
1. These findings provides evidence that gene-gene interactions between p11, tPA and BDNF are all associated with post stroke depression. PMID: 29028593
2. Underexpression of Tissue plasminogen activator is associated with diabetic foot syndrome. PMID: 28193577
3. By mediating the tPA response in macrophages, the NMDA-R provides a pathway by which the fibrinolysis system may regulate innate immunity. PMID: 28684538
4. Data suggest that protein aggregates interact with tissue-type plasminogen activator and plasminogen to efficiently generate plasmin; this aggregate-bound plasmin is shielded from inhibition by alpha-2-antiplasmin and degrades protein aggregates to release smaller, soluble but relatively hydrophobic peptide fragments; these fragments bind to and are cytotoxic to microglia (by not vascular endothelial cells). PMID: 28710283
5. Altogether, this preclinical study demonstrates that the tPA present in the blood stream is a key player of the formation of intracranial aneurysms. PMID: 28754830
6. tPA is a ligand of the N-terminal domain of the obligatory GluN1 subunit of NMDAR acting as a modulator of their dynamic distribution at the neuronal surface and subsequent signaling. PMID: 27831563
7. t-PA binds to Lys91 in the MBP NH2-terminal region and PLGbinds to Lys122 in the MBP COOH-terminal region. This proximity promotes the activation of Pg by t-PA. PMID: 28648598
8. local accumulation of cortisol is a causative factor for amnion epithelial apoptosis via activation of tPA/plasmin system toward the end of gestation. This may contribute to the ROM at both term and preterm birth. PMID: 27690691
9. We identified a homozygous null mutation in PLAT that abrogated t-PA level in patient cells. This is the first reported human knockout mutation of PLAT. The apparent association with hydranencephaly, diaphragmatic hernia and postnatal lethality requires further validation. PMID: 27417437
10. Tissue plasminogen activator (t-PA) antigen is a marker of cardiovascular risk. Exercise interventions associated with weight loss reduce t-PA antigen. Endurance training per se reduces t-PA antigen in healthy overweight men. PMID: 28254694
11. we reviewed current knowledge of mechanisms by which tPA can influence brain function in physiological and pathological conditions--REVIEW} PMID: 26626577
12. Data suggest that baseline levels of adiponectin, C-reactive protein, TPA, and fibrinogen or changes in these levels do not explain increased risk of diabetes type 2 in overweight women with glucose intolerance and histories of gestational diabetes. PMID: 25970741
13. Tissue plasminogen activator (tPA) may be a general factor in the immunological response to viruses. PMID: 26704613
14. tPA has a role in progression of periventricular white matter hyperintensities PMID: 26942412
15. These data indicate that oxygen-glucose deprivation-triggered Cav-1 S-nitrosylation interacts with tPA-induced ERK activation to augment MMP2 and 9 secretion and subsequent extracellular matrix degradation. PMID: 26881424
16. tPA-dependent activation of EGFRs leads to downregulation of NMDAR signaling and to subsequent neurotrophic effects. PMID: 26469972
17. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalization may improve safety of thrombolytic therapy. PMID: 25855589
18. Intravenous tissue plasminogen activator therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged>80 years) with acute ischemic stroke. PMID: 25329379
19. Review: t-PA function and regulation of its pericellular activity, with an emphasis on regulation of its gene expression. PMID: 24718307
20. data implicate MCP-1 as the key molecule governing tPA-induced fluid accumulation. The role of MCP-1 in the development of other exudative effusions warrants examination. PMID: 25474480
21. remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients PMID: 24815086
22. The results suggest roles for TLR3, TLR10, PLAT (n=2), VEGFA and DENND1B in susceptibility to chronic cavitary pulmonary aspergillosis. PMID: 24712925
23. shRNA-mediated silencing of PLAT in glioma-initiating cells phenocopied the effects of miR340 overexpression in vitro effects of miR340 overexpression in vitro PMID: 25627976
24. Activation of T cells triggered a rapid, 8.4-fold up-regulation of the serine protease tissue plasminogen activator, the protease target for neuroserpin. PMID: 25670787
25. Report tPA with a cutoff of 8.5 ng/mL has a high sensitivity and negative predictive value for exclusion of pulmonary embolism. PMID: 25339163
26. Data indicate that binding of tissue-type plasminogen activator (t-PA) to glucose-regulated protein 78 (GRP78) stimulates its amidolytic activity, activation of plasminogen (Pg), and cell proliferation. PMID: 25059665
27. Obese men exhibited lower levels of TPA activity compared to normal weight men. PMID: 25306554
28. plasminogen and plasmin but not tissue-type plasminogen activator have roles in regulating fibrinolysis by C-terminal lysines PMID: 22974122
29. It is involved in Amyloid-beta catabolism and clearance, which is particularly efficient for degrading Amyloid-beta aggregates. Thus, endogenous tPA could delay Alzheimer's disease pathogenesis by maintaining low levels of brain Amyloid beta. PMID: 24126163
30. Data suggest that tPA is required for bone repair and osteoblast proliferation; recombinant tPA stimulates proliferation of osteoblastic cell line. PMID: 24918201
31. Endogenously released tPA promotes neutrophil transmigration to reperfused tissue via proteolytic activation of plasmin and gelatinases. PMID: 24764453
32. There are correlations between t-PA, PAI-1 and some rotational thromboelastometry parameters in multiple myeloma patients. PMID: 24964508
33. Identify 3 loci associated with circulating tPA levels, the PLAT region, STXBP5, and STX2. Functional studies implicate a novel role for STXBP5 and STX2 in regulating tPA release. PMID: 24578379
34. Studies suggest that inadequate synthesis and release of tissue plasminogen activator (tPA) or low tPA activity be considered a critical component of schizophrenia pathophysiology. PMID: 24108470
35. Tissue plasminogen activator (t-PA) is a model of preterm intracerebral-intraventricular hemorrhages for the ontogenic window of vascular immaturity and protection against later neurodisabilities. PMID: 24709679
36. Data suggest plasma tissue plasminogen activator (t-PA) and fibrin fragment D-dimer levels are higher in abdominal aortic aneurysm patients than in controls; however, there is a negative relationship between t-PA and intraluminal thrombus thickness. PMID: 23959729
37. LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. PMID: 24129569
38. Renal impairment is associated with higher risk of symptomatic intracranial hemorrhage (sICH) after administration of intravenous tPA. PMID: 24145699
39. Successful thrombolysis can resolve DWI lesions but does not always improve the neurological symptoms. PMID: 21848677
40. Excess tissue-type plasminogen activator causes targeted Purkinje cell degeneration and ataxia. PMID: 23939410
41. II genotype carrier osteomyelitis patients had lower PAI-1/tPA complex levels. PMID: 23570848
42. Intravenous thrombolysis with alteplase does not appear to increase the risk of hemorrhagic complications in these non-metastatic cancer patients, in absence of additional risk factors of bleeding. PMID: 23317922
43. The combination of recombinant PA and erythropoietin increases release of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and thereby potentially deteriorates ischemic stroke outcome. PMID: 23788583
44. Use of intraventricular tPA for aneurysmal subarachnoid hemorrhage surgery results in less vasospasm, fewer angioplasties, and fewer cerebrospinal fluid shunting procedures. PMID: 20559098
45. Persons who develop non-affective psychoses have lower levels of certain acute phase proteins, including tPA, at the time of birth. PMID: 23423137
46. This meta-analysis suggested that the -7351C/T polymorphism in TPA gene would be a risk factor for ischemic stroke. PMID: 23326456
47. These results suggest that retained tPA on vascular endothelial cells effectively activated plasminogen to plasmin. PMID: 23118500
48. The serine protease tissue plasminogen activator (tPA) and two matrix metalloproteinases, ADAMTS-4 and ADAMTS-5, were identified as Reelin cleaving enzymes. PMID: 23082219
49. Intraventricular fibrinolysis with recombinant tPA does not lead to increased perihemorrhagic edema after intracerebral hemorrhage. PMID: 23306318
50. VDAC binds tissue-type plasminogen activator (t-PA) on human neuroblastoma SK-N-SH cells PMID: 23161549
顯示更多

收起更多
相關疾病：

Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
亞細胞定位：

Secreted, extracellular space.
蛋白家族：

Peptidase S1 family
組織特異性：

Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
數據庫鏈接：

HGNC: 9051

OMIM: 173370

KEGG: hsa:5327

STRING: 9606.ENSP00000220809

UniGene: Hs.491582

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human